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DNA methylation in ductal carcinoma in
situ related with future development of
invasive breast cancer
Kevin C. Johnson1,2, Devin C. Koestler3, Thomas Fleischer4,5, Panpan Chen1,2, Erik G. Jenson6, Jonathan D. Marotti6,
Tracy Onega2,7,8, Vessela N. Kristensen4,5,9 and Brock C. Christensen1,2,10*
Abstract
Background: Ductal carcinoma in situ (DCIS) is a heterogeneous, pre-invasive lesion associated with an increased
risk for future invasive ductal carcinoma. However, accurate risk stratification for development of invasive disease
and appropriate treatment decisions remain clinical challenges. DNA methylation alterations are early events in the
progression of cancer and represent emerging molecular markers that may predict invasive recurrence more
accurately than traditional measures of DCIS prognosis.
Results: We measured DNA methylation using the Illumina HumanMethylation450K array of estrogen-receptor
positive DCIS (n = 40) and adjacent-normal (n = 15) tissues from subjects in the New Hampshire Mammography
Network longitudinal breast imaging registry. We identified locus-specific methylation differences between DCIS
and matched adjacent-normal tissue (95,609 CpGs, Q < 0.05). Among 40 DCIS cases, 13 later developed invasive
disease and we identified 641 CpG sites that exhibited differential DNA methylation (P < 0.01 and median |Δβ| > 0.1)
in these cases compared with age-matched subjects without invasive disease. The set of differentially methylated
CpG loci associated with disease progression was enriched in homeobox-containing genes (P = 1.3E-09) and genes
involved with limb morphogenesis (P = 1.0E-05). In an independent cohort, a subset of genes with progression-
related differential methylation between DCIS and invasive breast cancer were confirmed. Further, the functional
relevance of these genes’ regulation by methylation was demonstrated in early stage breast cancers from The
Cancer Genome Atlas database.
Conclusions: This work contributes to the understanding of epigenetic alterations that occur in DCIS and illustrates
the potential of DNA methylation as markers of DCIS progression.
Keywords: Breast, Methylation, Array, DCIS, Cancer, TCGA
Background
Ductal carcinoma in situ (DCIS) is a non-invasive pre-
cursor lesion to invasive ductal carcinoma and is fre-
quently diagnosed upon screening mammography. In
2015, more than 60,000 DCIS diagnoses are expected in
the USA, accounting for over 25 % of new breast cancer
cases [1]. Importantly, the risk of developing invasive
breast cancer among women with DCIS is significantly
increased compared to the general population [2, 3].
Standard treatment of DCIS focuses on preventing the
development of invasive breast cancer with at least local
surgical excision to remove the proliferative lesion, al-
though more extensive treatment including mastectomy
is sometimes performed [4, 5]. The risk of local recur-
rence in patients treated with excision alone has been re-
ported to be as high as 25 % over 10 years [6]. However,
a majority of patients will never develop invasive disease
once treated, and so there exists a growing concern that
a subset of DCIS patients may be receiving excessive
treatment [7, 8]. Overtreatment can potentially subject
the patient to unnecessary risk of treatment, without
* Correspondence: Brock.Christensen@dartmouth.edu
1Department of Pharmacology and Toxicology, Geisel School of Medicine at
Dartmouth, HB 7650, Remsen 611, Hanover, NH 03755, USA
2Department of Epidemiology, Geisel School of Medicine at Dartmouth, HB
7650, Remsen 611, Hanover, NH 03755, USA
Full list of author information is available at the end of the article
© 2015 Johnson et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Johnson et al. Clinical Epigenetics  (2015) 7:75 
DOI 10.1186/s13148-015-0094-0
potential benefit, and burden the health care system [9].
Thus, identifying differential risks of developing invasive
breast cancer among DCIS patients may improve patient
outcomes and reduce healthcare costs.
The deregulation of epigenetic modifications, such as
DNA methylation, is an early event in breast carcinogenesis
[10, 11, 5, 12]. The addition of a methyl group to a cytosine
residue followed by a guanine (CpG) is recognized to be an
important regulator of gene expression and chromosomal
stability [13]. Although DNA methylation deregulation oc-
curs early in carcinogenesis, the patterns of epigenetic alter-
ations associated with development of invasive disease
remain unclear. DNA methylation alterations are potential
markers for DCIS outcome prediction and may identify cel-
lular changes that modulate tumor progression. Previous
studies have highlighted that DNA methylation alterations
are widespread in invasive breast carcinoma and result in
cellular dysfunction [14–18]. However, few studies have in-
vestigated the epigenetic alterations that occur in earlier
stages of disease, and of those that have, many used a can-
didate gene approach [5, 19, 20, 10, 21, 22]. Accordingly,
the identification of DNA methylation alterations that can
inform risk of subsequent invasive disease has the potential
to both impact clinical treatment decisions and improve
our understanding of cancer progression.
In this study, we identified subjects through the New
Hampshire Mammography Network (NHMN) and in-
vestigated DNA methylation patterns in estrogen-recep-
tor (ER) positive DCIS samples for their relation with
time to diagnosis of invasive breast cancer. We have
made use of a unique resource in the NHMN, which fol-
lows patients longitudinally, to examine DCIS of women
who did and did not develop invasive disease over the
same period of time. Here, we have used genome-wide
DNA methylation arrays to comprehvensively identify
DCIS-specific alterations in DNA methylation that differ
in these two groups. We subsequently extended our
findings to independent populations of DCIS and inva-
sive ductal carcinomas to further explore disease-specific
methylation deregulation and provide evidence for the
potential impact of these alterations on gene expression
[15]. Through these analyses, we have identified epigen-
etic changes in ER positive DCIS that may contribute to
increased risk of developing invasive breast cancer.
Results
Unsupervised clustering of DNA methylation in ductal
carcinoma in situ
Patient demographic data and DCIS pathologic character-
istics are presented in Table 1. To characterize DNA
methylation patterns of DCIS tissues (n = 40) and available
matched adjacent-normal samples (n = 15), we measured
genome-wide DNA methylation using the Infinium
HumanMethylation450 BeadArray. The scheme of our
analysis strategy for identifying deregulated methylation in
DCIS is depicted in Additional file 1: Figure S1. First, we
performed unsupervised hierarchical clustering of the
10,000 most variable DNA methylation loci and observed
two distinct clusters of methylation profiles among DCIS
samples (Figure. 1). The optimal number of two clusters
was verified by a resampling based unsupervised consen-
sus clustering method (Additional file 2: Figure S2) [23].
There was no significant enrichment for membership in
either methylation cluster for DCIS grade, subsequent
diagnosis of invasive breast cancer, or subject age. Next,
we assessed locus-specific patterns of differential methyla-
tion between DCIS tissues and matched adjacent-normal
breast tissue at single base resolution fitting linear mixed
effects models across 55 tissues (40 DCIS and 15 adjacent
normal). This analysis revealed profound alterations in
global methylation patterns (Additional file 3: Figure S3)
with the identification of 95,609 differentially methylated
CpGs significant after correction for multiple comparisons
(Q < 0.05, 20.3 % of CpGs).
Methylation patterns and development of invasive breast
cancer
To identify DNA methylation related with subsequent
development of invasive breast cancer, we fit Cox pro-
portional hazards models to examine the association be-
tween time-to-event data and the DNA methylation
values at each CpG locus independently (beta-value) and
adjusted for age and DCIS grade. We identified 641
CpGs, representing 397 genes, whose methylation was
associated with development of invasive disease (P <
0.01, with at least 10 % change in methylation,
Additional file 4: Table S1). The strongest associations
with development of invasive ductal carcinoma (IDC)
are presented in Table 2 and representative plots of cu-
mulative incidence for high and low methylation groups
(stratified by median DNA methylation values at a given
CpG) are shown in Fig. 2. Notably, among the 641 CpG
progression-associated loci there were 276 CpGs
(Additional file 4: Table S1) that exhibited differential
methylation between DCIS and adjacent normal as well
as further directionally consistent methylation alter-
ations in subjects that ultimately progressed to invasive
disease (Additional file 5: Figure S4 for representative
plots). As expected, a stratified analysis determined that
the strength of association was stronger with an ipsilat-
eral IDC to DCIS outcome compared with a contralat-
eral IDC outcome (Additional file 6: Table S2). Among
DCIS patients with a subsequent diagnosis of invasive
breast cancer, sidedness was not related with the methy-
lation clusters defined in Fig. 1.
We next sought to identify common biological pro-
cesses, pathways, and molecular functions with enrich-
ment among genes with progression-related methylation
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using the set of 641 CpG loci. Among the 375 Database
for Annotation, Visualization, and Integrated Discovery
(DAVID) genes that had at least one of the 641 differen-
tially methylated CpGs, an overrepresentation of homeo-
box genes (8.54-fold enrichment, P = 1.3E-09) and limb
morphogenesis genes (4.9-fold enrichment, P = 1.0E-05)
were identified (Additional file 7: Table S3). A majority
(70.3 %, Additional file 4: Table S1) of progression-
related CpGs are located within or in close proximity to
genes. Nearly 50 % of progression-related CpGs that ex-
hibited losses in methylation were open sea probes,
while only 9.5 % (Additional file 8: Table S4) tracked to
CpG Islands. In contrast, 31.4 % of CpG loci with gains
in DNA methylation tracked to CpG Islands (Additional
file 8: Table S4). To further examine the nature of
progression-related methylation in DCIS, we evaluated
the potential enrichment of genomic features among the
641 CpG loci. We observed a substantial enrichment of
polycomb group target genes (PCGTs) (P = 7.3E-07,
Table 3), open sea probes (P = 1.5E-04, Table 3), and
informatically predicted enhancer regions (P = 1.8E-22,
Table 3) among progression-related CpG loci. CpG loci
that were located in CpG islands were depleted among
progression-related loci (P = 9.8E-07, Table 3), and we
did not observe enrichment of progression-related CpGs
to CpG island shores (P = 0.06, Table 3), CpG island
shelves (P = 0.36, Table 3), or transcription factor binding
sites (TFBSs) (P = 0.89, Table 3).
Extension to an independent set of DCIS and IDC samples
An independent cohort of unmatched ER positive pure
DCIS (n = 17) and ER positive invasive ductal carcin-
omas (IDC, n = 115) with methylation data from the
same array platform was identified to validate differential
methylation of progression-related genomic regions be-
tween DCIS and IDC. While data on subsequent diagno-
sis of invasive breast cancer were not available for DCIS
cases in the independent cohort, increasing invasive po-
tential may be reflected in the methylation changes that
exist between DCIS and IDC. Comparing DCIS and IDC
in the independent cohort revealed 3000 CpGs that were
differentially methylated (P < 0.01, at least 10 % change,
Additional file 9: Table S5). Overall, four CpGs were sig-
nificantly differentially methylated in both populations
(P < 0.01, at least 10 % change, Additional file 10: Table
S6). In an expanded gene-level analysis, there were 397
genes related with the 641 CpG progression-associated
loci. Among this gene list were 72 genes (18.1 %,
Additional file 9: Table S5) that experienced differential
methylation between DCIS and IDC in the independent
Table 1 New Hampshire Mammography Network patient and DCIS characteristics
All DCIS No invasive BRCA Invasive BRCA
Covariate n = 40 n = 27 (67.5 %) n = 13 (32.5 %) P value
Age (years)
Range 37–78 37–78 38–76
Median 59 63 52
Mean (sd) 58.2 (12.8) 59.1 (13.0) 56.5 (12.9) 0.55
Follow-up time (years)
Median 7.01 8.55 2.94
Range 0.94–15.49 2.85–15.49 0.94–10.33 1.60E-04
Grade
Low/Intermediate (%) 28 (70.0) 17 (63.0) 11 (84.6)
High 12 (30.0) 10 (37.0) 2 (15.4) 0.27
Tumor size (cm)
Median 1.20 1.4 1.15
Range 0.15–7.5 0.2–7.5 0.15–2.1
Missing 8 5 3 0.64
Family history of breast cancer
No (%) 25 (62.5) 17 (63.0) 8 (61.5)
Yes 15 (37.5) 10 (37.0) 5 (38.5) 1.0
Menopausal status
Pre-menopausal (%) 15 (37.5) 9 (33.3) 6 (46.2)
Post-menopausal 25 (62.5) 18 (66.7) 7 (53.8) 0.59
T-tests or Wilcoxon tests were applied for numeric variables, while Fisher’s exact test was used for count data
P value represents results from univariate tests between study groups
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cohort. An unsupervised clustering of DNA methylation
from the 72 shared genes (77 CpGs) distinguished a subset
of DCIS subjects who later developed invasive disease
(Additional file 11: Figure S5). In the independent cohort
results, 28 out of 72 genes had a methylation change in the
same genomic region (i.e., promoter region, gene body re-
gion, and same direction as CpGs that were identified in
the discovery cohort. Restriction to these 28 genes did not
improve clustering (Additional file 11: Figure S5). A DAVID
analysis revealed that genes associated with mesenchymal
cell differentiation experienced the greatest enrichment
among the 72 gene-set, but the finding did not reach statis-
tical significance (1.73-fold enrichment, P = 0.72).
Assessment of methylation alterations and gene
expression in a set of primary TCGA breast tumors
Next, we investigated the relation of methylation alter-
ation with gene expression for progression-related CpGs.
Methylation of progression-related CpGs was strongly
correlated with gene expression in Stage I invasive breast
cancers; 101 out of 384 CpGs were significantly corre-
lated (P < 0.01, Additional file 12: Table S7). Among the
strongest associations between methylation and expres-
sion were CpG sites associated with TMEM139, HOXB2,
and TBX1 genes as well as the long non-coding RNA
HOTAIR (Fig. 3). As expected, a large majority (87.1 %)
of significant associations between methylation and gene
expression were negative correlations. The dependency
of regulation of gene expression by methylation on gen-
omic context was also apparent. A majority of the CpGs
whose methylation was positively correlated with expres-
sion were located in gene bodies (69.3 %), while those
CpGs negatively correlated with expression were equally
likely to be associated with promoter regions and first
exons of genes (48.9 %) or the gene body (47.7 %).
Discussion
A challenge in the management of DCIS is variability in
risk of developing invasive breast cancer. Decisions re-
garding treatment are complicated by a lack of reprodu-
cible clinical and pathologic factors that can reliably
predict risk of future invasive disease after surgical exci-
sion. Identification of molecular alterations differentiat-
ing lesions that will remain indolent from those that will
likely acquire an invasive phenotype begins to address a
critical need to provide more accurate risk assessment.
Emerging evidence from the initial stages of cancer devel-
opment suggests that the patterns of DNA methylation, a
stable mark capable of transcriptional control, are deregu-
lated early and may serve as a predictor of malignant po-
tential [19, 21, 5]. The present study aimed to characterize
the patterns of epigenetic deregulation that occur in the
early stages of breast cancer by investigating genome-wide
methylation patterns in DCIS and adjacent-normal tissue.
Fig. 1 Unsupervised clustering and heat map of DNA methylation in DCIS samples (n = 40). Unsupervised hierarchical clustering heat map based
on Manhattan distance and average linkage of the 10,000 CpG loci with the greatest variance
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We identified methylation of CpG loci that were strongly
associated with development of invasive breast cancer.
Notably, some of these alterations exhibited further
change when comparing DCIS with invasive tumors. The
CpG loci related to disease progression were highly
enriched for homeobox family of proteins and genomic
features such as polycomb group gene targets. Import-
antly, CpGs with progression-related changes in methyla-
tion in DCIS had strong correlations with gene expression
in an independent set of early stage ER positive breast
cancers, suggesting that differential methylation of these
sites may contribute to an increased risk of invasion
through aberrations in gene expression.
DCIS represents a direct precursor to invasive ductal
carcinoma. Altered patterns of DNA methylation have the
ability to the ability to modify the regulation of gene
expression, impact chromosomal instability, and have fre-
quently been observed in the early stages of breast cancer
[18]. However, the precise timing of molecular alterations
during tumorigenesis and how these changes to the breast
epigenome may influence the risk of becoming in-
vasive cancer remain incompletely defined. In prior work
and in this study, extensive epigenetic differences were
observed between adjacent-normal and DCIS tissues,
confirming that pre-invasive DCIS lesions harbor a high
degree of disruption in the methylation patterning of
Table 2 CpGs that possess the strongest associations between methylation levels and development of invasive ductal carcinoma
Illumina cg ID Chromosome Genomic location Genea Gene region HR (95 % CI)b P value
cg15786837 17 46806935 HOXB13 TSS1500 1.86 (1.37–2.53) 6.97E-05
cg22030072 2 119603673 EN1 Body 3.61 (1.90–6.88) 9.54E-05
cg13604794 17 48050338 DLX4 Body 1.92 (1.37–2.69) 1.47E-04
cg18944010 1 119522855 TBX15 5′UTR 2.12 (1.43–3.15) 1.88E-04
cg01002529 3 69591807 2.35 (1.50–3.70) 2.23E-04
cg08261841 7 142982463 TMEM139 5′UTR 0.56 (0.41–0.77) 2.82E-04
cg02926307 12 106520198 NUAK1 Body 0.40 (0.25–0.67) 3.60E-04
cg05075579 11 121421206 SORL1 Body 3.60 (1.77–7.30) 3.99E-04
cg15350661 12 322641 SLC6A12 5′UTR 2.31 (1.45–3.70) 4.10E-04
cg02770983 11 31822341 PAX6 Body 2.11 (1.39–3.19) 4.66E-04
cg00232535 7 5593287 0.47 (0.30–0.72) 4.79E-04
cg18343474 1 229566908 1.93 (1.33–2.80) 4.87E-04
cg00725138 22 19716556 0.50 (0.34–0.74) 5.34E-04
cg03695909 X 47346601 0.30 (0.15–0.59) 5.49E-04
cg26236177 14 61110649 1.77 (1.28–2.44) 5.60E-04
cg13434989 13 78493305 EDNRB TSS1500 1.83 (1.30–2.58) 5.67E-04
cg24006505 6 41337238 1.95 (1.33–2.58) 6.04E-04
cg04636194 X 49594154 PAGE4 5′UTR 0.43 (0.27–0.70) 6.07E-04
cg23429749 14 102050815 0.47 (0.31–0.73) 6.12E-04
cg05231018 17 46806763 HOXB13 TSS1500 1.70 (1.25–2.29) 6.18E-04
cg02492708 16 2005062 RPL3L TSS1500 0.50 (0.34–0.75) 6.24E-04
cg21211271 1 6265071 RNF207 TSS1500 2.37 (1.44–3.90) 6.48E-04
cg16009714 17 70241415 3.48 (1.70–7.12) 6.60E-04
cg00321709 10 135341933 CYP2E1 Body 2.04 (1.35–3.08) 6.69E-04
cg20401252 2 5834062 SOX11 1stExon 1.90 (1.31–2.73) 6.70E-04
cg19827511 14 93580644 ITPK1 Body 0.56 (0.39–0.78) 6.86E-04
cg10827488 11 113953838 ZBTB16 Body 3.42 (1.68–6.96) 6.97E-04
cg04327247 9 100564659 0.50 (0.34–0.75) 7.84E-04
cg26511386 7 142982262 TMEM139 5′UTR 0.52 (0.36–0.76) 8.02E-04
cg00332067 12 55004429 GLYCAM1 TSS200 2.10 (1.36–3.24) 8.30E-04
aMissingness represents a CpG locus that does not track to a gene
bFor each 10 % change in methylation, Cox proportional hazards models were adjusted for subject age and DCIS grade
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ductal epithelial cells [24]. The striking difference between
DCIS and tissues with no histologic evidence of malig-
nancy provides additional evidence that epigenetic alter-
ations in breast cancer are early events. Importantly, the
delineation of methylation changes in DCIS compared to
normal tissue helps to differentiate those early events that
prime cells with oncogenic insults from later events (i.e.,
events measured in invasive breast cancer) that may in-
crease malignant potential.
It is clear that pronounced molecular alterations occur
during the normal to DCIS transition; however, genetic al-
terations to explain the divergent gene expression patterns
between in situ and invasive breast carcinomas have not
been observed [25]. Epigenomic changes represent poten-
tial molecular attributes that define whether a carcinoma
remains indolent or shifts toward an invasive phenotype.
Indeed, we observed that altered DNA methylation associ-
ated with an invasive disease diagnosis preferentially tar-
geted gene groups were involved with key developmental
pathways. For instance, DNA methylation of informati-
cally predicted enhancer regions was enriched among pro-
gression-related CpGs. Interestingly, dysregulation of
DNA methylation at these distal regulatory sites has previ-
ously been related with the expression of cancer genes
[26]. Homeobox genes and other developmental transcrip-
tion factors become preferential targets of de novo methy-
lation in DCIS, consistent with previous associations
between homeobox gene methylation and recurrence in
invasive breast cancers [21, 27]. Together, these data pro-
vide evidence that perturbations in methylation among
homeobox genes may promote a transformed and invasive
phenotype. Similarly, biological processes that were not
shown to be enriched via DAVID, but present among the
differentially methylated loci, included Polycomb group
protein target genes (PCGTs). Polycomb group proteins
reversibly repress their target genes that are required for
differentiation and necessary to promote the self-renewal
potential of stem cells [28]. In our study, the PCGTs were
substantially more likely to have progression-specific
DNA hypermethylation than non-targets providing evi-
dence that acquisition of DNA methylation at these genes
could predispose cells to malignant transformation. In
summary, genes involved in developmental processes are
dysregulated early in disease development and may
Fig. 2 Cumulative incidence of invasive breast cancer diagnosis stratified by the median methylation in DCIS of each CpG into high or low methylation
groups. a Increased methylation in DCIS of a CpG in the south shore of a HOXB13 promoter CpG island is associated with invasive breast cancer
outcome (HR = 1.86, 95 % CI, 1.37–2.53) (high-methylation beta-value range, 0.14–0.71, low-methylation beta-value range, 0.03 - 0.13). b Increased
methylation in DCIS of a gene body CpG island site in EN1 is associated with invasive breast cancer outcome (HR = 3.61, 95 % CI, 1.90–6.88)
(high-methylation beta-value range, 0.27–0.58, low-methylation beta-value range, 0.069 - 0.27). c Increased methylation in DCIS of a gene
body CpG island site in DLX4 is associated with invasive breast cancer outcome (HR = 1.92, 95 % CI, 1.37–2.69) (high-methylation beta-value
range, 0.31–0.78, low-methylation beta-value range, 0.078–0.31). d Increased methylation in DCIS of a CpG site in the south shore of a CpG
island in the 5′’UTR of TBX15 is associated with invasive breast cancer outcome (HR = 2.12, 95 % CI, 1.43–3.15) (high-methylation beta-value range,
0.42–0.82, low-methylation beta-value range, 0.13 - 0.39)
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represent critical events that are exacerbated as ductal
cells progress to a more malignant phenotype.
At the gene level, the strongest locus-specific associa-
tions with progression tracked to genes with previously
demonstrated involvement in carcinogenesis. For example,
overexpression of EN1 is associated with pro-survival in
basal-like breast cancer [29]; HOXB13 hypermethylation
has been shown to be a late event in breast tumorigenesis
and is associated with invasiveness [30, 31]; increased ex-
pression of DLX4 reduces invasion in vitro and metastasis
in vivo [32]; and increased TBX15 methylation was a poor
prognostic indicator in prostate cancer [33]. Moreover,
there were 276 CpG loci including those that track to the
HOXB13, DLX4, and TBX15 genes that exhibited a signifi-
cant gain or loss of methylation from normal to DCIS and
were further hypermethylated or hypomethylated in le-
sions from women with a subsequent diagnosis of invasive
disease. Additional deregulation of methylation at these
sites suggests that a greater proportion of cells harbor al-
terations associated with an invasive phenotype. Based on
these preliminary results, it seems reasonable to envision
a clinical scenario where leveraging both pathologic and
molecular characteristics of DCIS and surrounding normal
tissues will contribute to decisions of whether more or less
aggressive treatment and/or monitoring is warranted.
The results from comparing methylation in an inde-
pendent set of DCIS tissues with IDC indicated that dif-
ferences between invasive disease and DCIS overlap with
those that potentiate development of an invasive pheno-
type. Our DAVID analysis—despite being best suited for
gene sets between 100–2000 genes—of the 72 genes
shared between data sets suggests that epigenetic de-
regulation of genes involved in cellular development and
differentiation is likely a defining feature progression to
invasive disease [34]. Further, alterations that are critical
for development of an invasive phenotype may occur in
DCIS and once the cancerous cells escape from the duct
additional epigenetic programming may be required for
further progression or metastasis. Regardless, in early
stage invasive breast tumors from TCGA, we observed
that progression-related CpGs exhibit strong correla-
tions with gene expression. Our results provide evidence
that the acquisition or loss of DNA methylation at the
identified progression-related CpGs has a functional im-
pact on gene expression. Examples of potential critical
methylation changes include the following: GATA2 ex-
pression (methylation was positively correlated with ex-
pression among the TCGA samples) has been shown to
be elevated in breast cancer and serves to repress PTEN
expression [35], HOXB2 for which increased methylation
is associated with bladder cancer invasiveness [36], and
the long non-coding RNA HOTAIR, which demon-
strated increases in methylation associated with progres-
sion and was also positively correlated with expression
in TCGA tumors. Interestingly, HOTAIR is a long non-
coding RNA responsible for Hox gene silencing.
HOTAIR is increased in expression in primary breast tu-
mors and metastases, and loss of HOTAIR can inhibit
cancer invasiveness [37]. Early methylation events that
target homeobox genes in DCIS may, in part, be respon-
sible for the aberrant gene expression of homeobox
genes that has been observed in cancer [38]. Overall, we
observed that progression-related methylation patterning
is strongly related with transcription of genes that are
known to be associated with the invasive phenotype.
The major objective of our work was to determine epi-
genetic events that contribute to development of inva-
sive breast cancer. Our study is strengthened by the use
of time-to-event data for subsequent diagnosis of inva-
sive breast cancer. The longitudinal aspect of the cohort
is an important distinction from previous cross-sectional
approaches that have examined DCIS and invasive dis-
ease with a lack of clinical follow-up. In spite of this,
each cohort in our investigation had a limited sample
size. Therefore, future studies of methylation alterations
in additional DCIS specimens with follow-up data are
needed to further confirm and more precisely define po-
tential biomarkers of risk stratification among DCIS sub-
jects. In addition, future population-based studies that
collect samples from the same individual across the
spectrum of disease and investigate the relation of DNA
methylation with breast cancer risk factors may also be
informative for enhanced prediction of risk for disease
progression.
Conclusions
Our approach identified methylation alterations present
in DCIS that may contribute to breast tumorigenesis
and development of invasive disease. Progression from
DCIS to invasive disease represents a substantial in-
crease in the risk of breast cancer mortality, and identifi-
cation of disease progression markers for DCIS is
needed. We have provided evidence for methylation al-
terations that are associated with development of inva-
sive disease and defined specific epigenetic programs in
DCIS disease progression that are particularly suscep-
tible to deregulation. Further examination of these alter-
ations is warranted to demonstrate their potential utility
in defining risk for subsequent invasive disease and thus
impact treatment decision-making.
Availability of supporting data
Data for all NHMN DCIS DNA methylation microarray
experiments are available on the National Center for Bio-
technology Information’s gene expression omnibus under
the accession number GSE66313.
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Methods
Study design and patient population
Pure ductal carcinoma in situ (DCIS) samples for 43
subjects were identified through the New Hampshire
Mammography Network (NHMN), under the approval
of the Institutional Review Board. The NHMN is a state-
based mammography registry that records information
from breast imaging exams and subsequent pathology,
cancer, and vital status outcomes for consenting women
[39]. For the present report, the analyses were based on
samples collected from women who underwent resection
of a breast lesion at Dartmouth-Hitchcock Medical Center
(Lebanon, NH, USA). Three DCIS samples were removed
from analysis in the quality assessment and control steps
of methylation data processing detailed below. Among ER
positive DCIS cases (n = 40), there were 13 patients with a
subsequent diagnosis of invasive ductal carcinoma (IDC)
and 27 age-matched subjects with similar follow up time
who did not have a subsequent diagnosis of IDC. The time
to progression and date of last known follow-up for those
without subsequent diagnosis were recorded; median clin-
ical follow-up for this cohort was 7 years. Slides from all
subjects underwent central pathology review by a breast
pathologist (JDM) to confirm diagnosis of ductal carcin-
oma in-situ and record histopathologic features. Multiple
(at least two) 2-mm tissue cores were taken from the ar-
chived formalin-fixed paraffin-embedded (FFPE) blocks
from selected areas of DCIS and adjacent-normal tissue for
DNA extraction and bisulfite modification. The available
block with the greatest, homogeneous amount of target tis-
sue was selected for DNA extraction. The patient-matched
normal breast tissues adjacent to DCIS did not have any
Table 3 Enrichment of genomic features among 641 progression-related loci
A
Polycomb Group Target Genes (PCGT) PCGT Target NonPCGT Target
All array CpGs 49,054 (12.3 %) 348,546 (87.7 %)
Progression-related CpGs 123 (19.2 %) 518 (80.8 %) *P value = 7.3E-07
B
Enhancer Regions Enhancer Nonenhancer
All array CpGs 72,289 (18.2 %) 325,311 (81.8 %)
Progression-related CpGs 176 (33.5 %) 465 (66.5 %) *P value = 1.8E-22
C
CpG Island Status CpG Island NonCpG Island
All array CpGs 145,618 (36.6 %) 251,982 (63.4 %)
Progression-related CpGs 176 (33.5 %) 465 (66.5 %) *P value = 9.8E-07
D
Open Sea Open Sea Nonopen Sea
All array CpGs 125,650 (31.6 %) 271,950 (68.4 %)
Progression-related CpGs 248 (38.7 %) 393 (61.3 %) *P value = 1.5E-04
E
CpG Island Shore CpG Island Shore NonCpG Island Shore
All array CpGs 92,703 (23.3 %) 363971 (76.7 %)
Progression-related CpGs 170 (26.5 %) 471 (73.5 %) *P value = 6.1E-02
F
CpG Island Shelf CpG Island Shelf NonCpG Island Shelf
All array CpGs 33,629 (8.5 %) 363,971 (91.5 %)
Progression-related CpGs 176 (7.3 %) 594 (92.7 %) *P value = 0.35
G
TFBSany TFBS NonTFBS
All array CpGs 127 688 (32.2 %) 269 912 (67.8 %)
Progression-related CpGs 204 (31.8 %) 437 (68.2 %) *P value = 0.89
CpGs among the 641 progression-related loci in DCIS are enriched for localization to A Polycomb group target genes (PCGTs), B informatically predicted enhancer
regions, C depleted for localization to CpG Islands, and D enriched at Open Sea probes. Progression-related loci did not exhibit enrichment of E CpG Island shores,
F CpG Island shores, or G any transcription factor binding site (TFBS)
*Fisher’s exact test
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histologic evidence of malignancy and were randomly se-
lected from 15 subjects. Patients were not treated with
neoadjuvant therapy, and subsequent invasive ductal car-
cinoma samples from matched DCIS subjects were not
evaluated in this study. Material for the independent popu-
lation was obtained from ER positive pure DCIS (n = 17)
and ER positive IDC (n = 115) as described in GSE60185
[24]. All samples were taken in compliance with the
Helsinki Declaration.
Array-based DNA methylation assessment and quality
control
Formalin-fixed paraffin embedded tissue samples were
disrupted before subsequent DNA purification using the
TissueLyserII (Qiagen, Valencia, CA, USA) for 1 min at
30 Hz. DNA was then isolated using the QIAamp DNA
formalin-fixed paraffin embedded tissue kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
protocol. Genomic DNA was bisulfite modified using
the EZ DNA methylation kit (Zymo Research, Irvine,
CA) and bisulfite-converted DNA from formalin-fixed
paraffin embedded (FFPE) samples were processed as
described in the Infinium FFPE Restoration guide (Illu-
mina, San Diego, CA, USA) [40–42]. A recent study
established the minimal effect that FFPE restoration has
on methylation values via the demonstration of a very
strong correlation between methylation β-values from
paired fresh frozen and FFPE tissues [42]. After FFPE
restoration, the resulting material was used as input for
the hybridization on the Infinium HumanMethyla-
tion450 BeadChip (Illumina, San Diego, CA, USA),
which has demonstrated high concordance with other
bisulfite modification techniques such as pyrosequencing
[17, 43–45]. Samples were randomized to plates and
subjected to epigenome-wide DNA methylation assess-
ment. The methylation status for each CpG locus was
calculated as the ratio of fluorescent signals (β =Max
(M, 0) / [Max(M,0) +Max(U,0) + 100]), ranging from 0
(non-methylated) to 1 (completely methylated), using
average probe intensity for the methylated (M) and
unmethylated (U) alleles. For preprocessing of the
methylation data, we used the Chip Analysis Methyla-
tion Pipeline (ChAMP version 0.98.3) package in R [46].
Briefly, ChAMP takes the raw IDAT files from the arrays
using data import, assesses the quality of probes and
samples, provides adjustment for probe type bias, and al-
lows for adjustment for batch-effects. As a part of the
quality control step, three DCIS samples were removed
because greater than 20 % of probes among these sam-
ples had a detection P-value greater than 0.01. In total,
there were 40 DCIS and 15 adjacent-normal samples
that passed quality control (QC) and were included in
subsequent analyses. Probes were dropped from future
analyses if the median detection P-value was >0.01
across all samples, which left a total of 397,600 out of
485,577 probes that passed QC. In the ChAMP package,
Fig. 3 Genes whose expression levels correlated with methylation level of progression-related CpGs from Stage I ER positive TCGA breast tumors.
Bubble points represent genes that demonstrate a significant relationship between methylation of a CpG and expression of its nearby gene in a
genomic-context dependent manner. Increasing bubble diameter corresponds with decreasing P value. CpG position relative to gene location is
plotted versus correlation coefficient between CpG methylation and gene expression
Johnson et al. Clinical Epigenetics  (2015) 7:75 Page 9 of 12
we implemented beta-mixture quantile normalization
(BMIQ) to adjust the data for bias introduced by the
Infinium type 2 probe design [47]. Next, we corrected
for potential batch-effects by applying the ComBat
normalization method using the R-package “sva” [48].
Data for all DNA methylation microarray experiments
are available on National Center for Biotechnology In-
formation’s gene expression omnibus [35] in accordance
with MIAME under the accession number GSE66313.
Statistical analysis
Data assembly
All methylation data were analyzed using the R software
environment, version 3.0.3 (www.r-project.org).
Unsupervised hierarchical clustering
Hierarchal clustering was based on Manhattan distance
and average linkage of the 10,000 most variable CpG
loci. The optimal number of clusters was established
based on 1000 resampling interactions of K-means clus-
tering for K = 2,3,4,5, with Euclidean distance being the
distance metric implemented in the “ConsensusCluster-
Plus” R package [49].
Locus-by-locus analysis for detecting differentially
methylated CpG loci
Locus-specific patterns of differential methylation be-
tween DCIS tissues (n = 40) and matched adjacent-
normal breast tissue (n = 15) were identified via linear
mixed effects models fit to each CpG independently,
modeling logit-transformed β-values as the dependent
variable and tissue-type and subject age as the independ-
ent variables. The linear mixed effects models included a
random effect term for subject to account for repeat
measures on the same subject. P values obtained from
our linear mixed effects models were adjusted for mul-
tiple testing using false discovery rate estimation. The Q
values were computed by the “qvalue” package in R and
a Q value < 0.05 was deemed statistically significant. To
identify epigenetic alterations associated with develop-
ment of invasive disease among DCIS patients, locus-
specific differences in DNA methylation of DCIS samples
were examined using Cox proportional hazards models
adjusted for subject age and DCIS grade (low/intermediate
or high) [50]. To reduce Type I error and maintain sensi-
tivity of discovery, we selected CpGs whose methylation
was associated with development of invasive breast cancer
at P < 0.01 and then limited our analyses to those CpG
sites that exhibited a median |Δβ| greater than 0.1. We
also implemented a stratified Cox proportional hazards
analysis to explore whether there were different strengths
in association between cases of ipsilateral (n = 7) and
contralateral (n = 6) to DCIS.
Independent cohort of pure DCIS and pure IDC
Preprocessing and normalization of this data have previ-
ously been described above (ChAMP), and the raw data
is available in Gene Expression Omnibus with accession
number GSE60185. To identify epigenetic alterations
that differentiate disease states (i.e., IDC compared with
DCIS), we fit via linear models to each CpG independ-
ently, modeling logit-transformed β-values as the
dependent variable and disease state as the independent
variable.
The Cancer Genome Atlas data
Level 3 normalized Illumina Infinium Human Methyla-
tion450 BeadChip and RNASeqV2 rsem.genes.normali-
zed_results data were downloaded from the TCGA
(http://cancergenome.nih.gov/). All Stage I ER positive
breast cancers from Caucasians were selected (n = 65).
Expression data and CpG sites from the 641 differen-
tially methylated loci were paired by gene symbol for the
65 samples, resulting in a total of 384 unique methyla-
tion and expression pairs used in the correlation ana-
lysis. The relation of methylation with gene expression
was evaluated with Spearman correlations.
Enrichment analyses of biological pathways and common
sequence features
The Database for Annotation, Visualization, and Inte-
grated Discovery was used for an analysis of molecular
pathways [34, 51]. In the DAVID analysis, the set of
genes represented on the Illumina HumanMethyla-
tion450 array that remained after QC was used as the
referent set and the set of genes associated with 641 pro-
gression-related CpG loci composed the gene set tested.
Enrichment analyses of common sequence features
among progression-related CpG loci were performed
using two-tailed Fisher’s exact tests. The Polycomb
group target genes (PCGT) status for a given CpG loci
was based on whether the gene associated with that
CpG was described as a PcG target in previously pub-
lished works [52–55]. Putative transcription factor bind-
ing sites (TFBSs) located within 50 bp of progression-
associated methylation of loci were obtained from the
tfbsConsSites track of the UCSC Genome browser [56].
Additional files
Additional file 1: Supplemental Figure S1. Diagram of analytic
strategy used to identify deregulated epigenetic patterns in DCIS and
their relation with invasive breast cancer development.
Additional file 2: Supplemental Figure S2. Consensus clustering of 40
samples and 10,000 most variable CpGs identified 2 clusters as the
optimal number.
Additional file 3: Supplemental Figure S3. Results from the locus-by-
locus examination of differential methylation between DCIS and normal-
adjacent to DCIS tissues.
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